|

Micronutrients in Health and Disease
Table
2:
Vitamin Functions, Deficiency Diseases,Toxicity Symptoms,
and Dietary Reference Intakes* |
Vitamin |
Functions/Roles
in metabolism |
Deficiency
Symptoms |
Toxicity
Symptoms |
Recommended
Dietary Allowance |
Vitamin A |
Bone growth, reproduction, cell
division, immunity, cell differentiation |
Clinical: Night blindness; total
blindness (rare in the U.S.)
Subclinical: May increase risk for respiratory and diarrheal
infections; decrease growth rate; slow bone develop–ment; and
decrease likelihood of survival from serious illness |
Birth defects, liver abnormalities,
reduced bone mineral density; central
nervous system disorders (eg, pseudotumor cerebri) |
Adults: Age 19+:
Males: 900 μg
Females: 700 μg
Infants/children: (*)
0–6 months: 400 μg
7–12 months: 500 μg
1–3 years: 300 μg
4–8 years: 400 μg
9–13 years: 600 μg
14–18 years (boys): 900 μg
14–18 years (girls): 700 μg
Pregnancy:
Age < 18: 750 μg
Age 19+ 770 μg
Lactation:
Age < 18: 1,200 μg
Age 19+: 1,300 μg |
Vitamin D
|
Maintenance of normal blood levels
of calcium and phos–phorus; promotes bone mineralization; regulates
cell growth, differentiation, immune function |
In children: rickets
In adults: osteomalacia |
Nausea, vomiting, poor appetite,
constipation, weakness, and weight loss; mental status changes;
hypercalcemia; calcinosis |
Adults:*
Ages19–70: 15 μg/600 IU
Ages 70+: 20 μg/800 IU
Infants /children: 0-12 months: 10 μg/400 IU* 1–18 years: 15 μg/600 IU
Pregnancy/ lactation: 15 μg/600 IU |
Vitamin E |
Antioxidant (protects cells against
free radicals); plays role in immune function and in DNA repair;
inhibits cell proliferation, platelet aggregation, and monocyte
adhesion1 |
Nerve degeneration in hands and
feet |
Can influence coagulation in some
persons with drug–induced vitamin K deficiency; anti–platelet
effect |
Adults:19+ years: 15mg
Infants/children: (*)
0–6 months: 4mg
7–12 months: 5mg
1–3 years: 6mg
4–8 years: 7mg
9–13 years: 11mg
14–18 years: 15mg
Pregnancy: 15mg
Lactation: 19mg |
Vitamin K |
Coenzyme for synthesis of proteins
involved in blood coagulation and bone metabolism |
Increase in prothrombin time; in
severe cases, hemorrhagic events |
None currently known |
Adults: 19+ years: (*)
Males: 120 μg
Females: 90 μg
Infants/children: (*)
0–6 months: 2 μg
7–12 months: 2.5 μg
1–3 years: 30 μg
4–8 years: 55 μg
9–13 years: 60 μg
14–18 years (boys): 120 μg
14–18 years (girls): 75 μg
Pregnancy/lactation:
Girls < 18 years: 75 μ g
Adults 19 + years: 90 µg |
Sources: National Institutes of Health, Office
of Dietary Supplements Web site (http://dietary–supplements.info.nih.gov/)
^see Azzi A Zingg, Nonantioxidant activities of vitamin E. Curr Med
Chem. 2004;11:1113–1133.
Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin
K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel,
Silicon, Vanadium, and Zinc. Washington, D.C.: National Academies
Press, 2000.
Institute of Medicine, Dietary Reference Intakes for Vitamin C, Vitamin
E, Selenium, and Carotenoids. Washington, D.C.:National Academies Press,
2000. IOM did not set an RDA for vitamins in this age group. Instead, an Adequate
Intake (AI) is used. According to the Institute of Medicine, “The AI is
a recommended average daily nutrient intake level, based on experimentally derived
intake levels or approximations of observed mean nutrient intake by a group (or
groups) of apparently healthy people that are assumed to be adequate. An AI is
established when there is insufficient scientific evidence to determine an Estimated
Average Requirement (EAR).” Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011. Available at: http://www.nap.edu/openbook.php?record_id=13050&page=1 . Accessed February 14, 2011.
Vitamin |
Functions
/Roles in Metabolism |
Deficiency Symptoms |
Toxicity Symptoms |
Recommended Dietary
Allowance |
Vitamin C |
Antioxidant; biosynthesis of connective tissue
components (collagen, elastin, fibronectin, proteoglycans,
bone matrix, and elastin–associated fibrillin); carnitine,
and neuro–transmitters |
Scurvy (involves deterioration of elastic tissue);
follicular hyperkeratosis, petechiae, ecchymoses, coiled hairs,
inflamed and bleeding gums, perifollicular hemorrhages, joint
effusions, arthralgia, and impaired wound healing; dyspnea,
edema, Sjögren syndrome, weakness, fatigue, depression |
Nausea, abdominal cramps, and diarrhea (from
supplements) |
Adults (> 19 years):
Males: 90mg
Females: 75mg
Infants/children: (*)
0–6 months: 40mg
7–12 months: 50mg
1–3 years: 15mg
4–8 years: 25mg
9–13 years: 45mg
14–18 years (boys): 75mg
14–18 years (girls): 65mg
Pregnancy:
Age < 18: 80mg
Age 19–50: 85mg
Lactation:
Age < 18: 115mg
Age 19+: 120mg |
Thiamine
(B1) |
Coenzyme in the metabolism of carbohydrates
and branched–chain amino acids |
Anorexia; weight loss; mental changes such
as apathy, decrease in short–term memory, confusion, and irritability;
muscle weakness; cardiomegaly; beriberi (polyneuritis) |
Oral forms: None currently known
Parenteral: Pruritus (rare: 1% of patients); extremely rare
anaphylactic reaction
IOM conclusion: Even high–dose IV use is relatively
safe |
Adults (> 19 years):
Males: 1.2mg
Females: 1.1mg
Infants/children: (*)
0–6 months: 0.2mg
7–12 months: 0.3mg
1–3 years: 0.5mg
4–8 years: 0.6mg
9–13 years: 0.9mg
14–18 years (boys): 1.2 mg
14–18 years (girls): 1.1 mg
Pregnancy/lactation: 1.4 mg |
Riboflavin (B2) |
Coenzyme in numerous redox reactions |
Ariboflavinosis; sore throat; hyperemia and
edema of pharyngeal and oral mucous membranes; cheilosis; angular
stomatitis; glossitis (magenta tongue); seborrheic dermatitis;
normochromic, normocytic anemia |
None currently known |
Adults (ages 19+):
Males: 1.3mg
Females: 1.1mg
Infants/children: (*)
0–6 months: 0.3mg
7–12 months: 0.4mg
1–3 years: 0.5mg
4–8 years: 0.6mg
9–13 years (boys): 0.9mg
14–18 years (boys): 1.3mg
9–13 years (girls): 0.9mg
14–18 years (girls): 1.0mg
Pregnancy: 1.4mg
Lactation: 1.6mg |
Niacin (B3) |
Coenzyme in numerous redox reactions |
Pellagra (pigmented rash, vomiting, constipation
or diarrhea, bright red tongue; neurological symptoms including
depression, apathy, headache, fatigue, and loss of memory) |
From nicotinamide: nausea, vomiting, and signs
and symptoms of liver toxicity (at intakes of 3,000 mg/day);
from nicotinic acid: same signs at 1,500 mg/day (most toxicity
related to pharmacologic use); hepatotoxicity (at doses of
3–9 g/day); blurred vision, toxic amblyopia, macular edema
(doses of 1.5–5g/day) |
Adult males and males >age 14: 16mg
Adult females and females >age 14: 14mg
Infants/children: (*)
0–6 months: 2.0mg
7–12 months: 4.0mg
1–3 years: 6.0mg
4–8 years: 8.0mg
9–13 years (boys): 12.0mg
Pregnancy: 18mg
Lactation: 17mg |
Panto–
thenic acid (B5) |
Component of coenzyme A; cofactor and acyl
group carrier for many enzymatic processes, and acyl carrier
protein, a component of the fatty acid synthase complex |
Extremely rare; irritability and restlessness;
fatigue; apathy; malaise; sleep disturbances; gastro–intestinal
complaints such as nausea, vomiting, and abdominal cramps;
neurobiological symptoms such as numbness, paresthesias, muscle
cramps, staggering gait |
None currently known |
Adults (ages 19+): 5.0mg
Infants/children: (*)
0–6 months: 1.7mg
7–12 months: 1.8mg
1–3 years: 2.0mg
4–8 years: 3.0mg
9–13 years (boys): 4.0mg
14–18 years (boys): 5.0mg
Pregnancy: 6.0mg
Lactation: 7.0mg |
Pyridoxine (B6) |
Coenzyme in the metabolism of amino acids,
glycogen, and sphingoid bases |
Seborrheic dermatitis, microcytic anemia, epileptiform
convulsions |
Sensory neuropathy with high (>100
mg) supplementary intake |
Adults:
Ages 19–50: 1.3mg
Age 51+ (males): 1.7mg
Age 51+ (females): 1.5mg
Infants/children: (*)
0–6 months: 0.1mg
7–12months: 0.3mg
1–3 years: 0.5mg
4–8 years: 0.6mg
9–13 (boys/girls): 1.0mg
14–18 years (boys): 1.3mg
14–18 years (girls): 1.2mg
Pregnancy: 1.9mg
Lactation: 2.0mg |
Folic acid |
Coenzymes are involved in DNA synthesis; amino
acid interconversions; single–carbon metabolism; methylation
reactions |
Early sign: hypersegmented neutrophils
Late sign:
macrocytic anemia (weakness, fatigue, difficulty concentrating,
irritability, headache, palpitations, shortness of breath) |
None in healthy individuals; may decrease phenytoin
levels and trigger seizures in patients with seizure disorder
(Neurology. 2005;64:1982); may precipitate or exacer–bate
neuropathy in vitamin B12–deficient individuals |
Adults (ages 19+): 400 µg
Infants/children: (*)
0–6 months: 65 µg
7–12months: 80 µg
1–3 years: 150 µg
4–8 years: 200 µg
9–13 years: 300 µg
14–18 years: 400 µg
Pregnancy: 600 µg
Lactation: 500 µg |
Vitamin B12 |
Cofactor for methionine synthase and L–methyl–malonyl–CoA
mutase; essential for normal blood formation and neurologic
function |
Pernicious anemia; neuro–logic manifestations
(sensory disturbances in the extremities; motor disturbances,
including abnormalities of gait); cognitive changes (loss of
concentration; memory loss, disorientation and frank dementia);
visual disturbances, insomnia, impotency, and impaired bowel
and bladder control |
None currently known |
Adults (ages 19+): 2.4 µg
Infants/children: (*)
0–6 months: 0.4 µg
7–12months: 0.5 µg
1–3 years: 0.9 µg
4–8 years: 1.2 µg
9–13 years: 1.8 µg
4–18 years: 2.4 µg
Pregnancy: 2.6 µg
Lactation: 2.8 µg |
Source: Institute of Medicine. Dietary Reference
Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate,
Vitamin B12, Pantothenic Acid, Biotin, and Choline (1998)
and Institute of Medicine (IOM). Dietary
Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington,
D.C.:National Academies Press, 2000. (*) IOM did not set an RDA
for vitamins in this age group. Instead, an Adequate Intake (AI)
is used. According to the Institute of Medicine, “The AI
is a recommended average daily nutrient intake level, based on
experimentally derived intake levels or approximations of observed
mean nutrient intake by a group (or groups) of apparently healthy
people that are assumed to be adequate. An AI is established
when there is insufficient scientific evidence to determine an
Estimated Average Requirement (EAR).”
Biotin |
Coenzyme in bicarbonate–dependent
carboxylation reactions (eg, acetyl–CoA carboxylase, pyruvate
carboxylase) |
Dermatitis, conjunctivitis, alopecia,
and central nervous system abnormalities (depression, lethargy,
hallucinations, and paresthesia of the extremities) |
None currently known |
Adults (ages 19+) (*): 30 µg
Infants/children: (*)
0–6 months: g
7–12 months: 6 µg
1–3 years: 8 µg
4–8 years: 12 µg
9–13 years: 20 µg
14–18 years: 25 µg
Pregnancy: 30 µg
Lactation: 35 µg |
Choline |
Synthesis and release of acetylcholine;
precursor for the synthesis of cell membrane components (phospholipids
and sphingomyelin), platelet activating factor, and betaine
(important in metabolism of homocysteine) |
Steatosis, liver damage |
Fishy body odor, sweating, salivation,
hypotension, mild hepatotoxicity |
Men (ages 19+): 550mg
Women (ages 19+): 425mg
Infants/children: (*)
0–6 months: 125mg
7–12months: 150mg
1–3 years: 200mg
4–8 years: 250mg
9–13 (boys/girls): 375mg
14–18 years (boys): 550mg
14–18 years (girls): 400mg
Pregnancy: 450 mg
Lactation:550 mg |
|